Pharmacy Toolkit

NOTE: You must login to your Alliance account to access the articles and resources below. Some content may only be accessible to Alliance members.

 

5/11/2020

Battling the Big Squeeze: How understanding demand and margin can improve brand performance
IQVIA provides information on how analytics can help defend your brand against the impacts of COVID-19, specifically within the pharmaceutical industry.

5/4/2020

IQVIA COVID-19 Tracker - May 1, 2020
IQVIA introduces new insights into the COVID-19 impact, provides a perspective on changes to R&D, and provides the latest survey feedback from healthcare practitioners.

5/4/2020

Symphony COVID-19 Weekly Trend Insights - April 17, 2020
Symphony Health introduces new trend insights into COVID-19 impact, case developments, and potential treatments.

4/20/2020

IQVIA COVID-19 Tracker - April 17, 2020
IQVIA introduces new insights into the COVID-19 impact, provides a perspective on changes to R&D, and provides the latest survey feedback from healthcare practitioners.

10/9/2019

Audio: Pharmacy Roundtable: Organizational Structures, Roles and Staffing
Health Alliance Plan and other member plans share and collaborate about their pharmacy department organizational structures and discuss challenges with staffing and managing the department.

5/30/2019

Presentation: Financial Transparency and Analytics for Managed Care Organizations
Truveris examines how best to create transparency throughout every stage of your PBM contract life-cycle, as well as align your internal management team to focus on a few key metrics and leverage industry trend analysis.

5/30/2019

Presentation: Management of biosimilars across the enterprise
Presbyterian Health Plan shares an overview of the process utilized with key medical group stakeholders in Gastroenterology & Rheumatology to develop and implement practice guidelines and protocols for the use of biosimilars across the enterprise.

5/30/2019

Presentation: Oncology utilization management
Scott & White Health Plan implemented a successful solution to address the challenge of cost management and benefits review for oncology services, presented at the Pharmacy Summit May 30, 2019.

5/29/2019

Presentation: Opioid overuse strategies
Sentara & SelectHealth share overviews of the programs and strategies they have employed to address both acute and chronic opioid overuse, detoxification programs in addition to prescriber interventions. Presented at the pharmacy summit held in Dallas on May 29 and 30, 2019.

5/29/2019

Presentation: Specialty Pharmacy Management Strategies & Innovations
The cost of specialty pharmacy is a rising concern for patients, providers, and payers. Cooperative Benefits Group reviews specialty trends in both cost and utilization as well as the drivers of specialty Rx growth and innovative approaches to reducing spend.

5/20/2019

Prescription Drugs Trends Analysis: Medicare Part D and Medicare
The Menges Group provides a 5-slide analysis of volume and expenditure trends in the prescription drugs industry for Medicare Part D and Medicaid. Included also is data about Specialty prescriptions.

5/17/2019

Specialty Pharmacy Industry Outlook: What's Next
A comprehensive overview of the Specialty pharmacy market including key trends, public policy, pricing and persceptives from Wall Street.

5/17/2019

PBM Payer Mergers and Integrations
In this April, 2019 presentation, Cleveland Research provides an in-depth overview of PBM payer mergers and integrations.

5/7/2019

Presentation: What Your PBM Doesn't Want You To Know - Delivering Savings and Better Care with Financial and Performance Transparency
Truveris pharmacy benefit experts Rahul Singal, MD and Ryan Hanes, MBA demonstrate how to create transparency throughout every stage of your PBM contract life-cycle, as well as align your internal management team to focus on a few key metrics and benchmarks.

4/22/2019

Alternative Models for Pharmaceutical Rebates
The combination of rising drug costs at the health system level and increasing financial stress for individual patients has triggered intense national concern. One target has come under particular scrutiny: rebates. This white paper provides policy perspectives on alternative models for pharmaceutical rebates.